by 
Market Overview:
Gastritis treatment aims to reduce stomach inflammation and prevent further damage. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2 blockers) are commonly used to treat gastritis. PPIs work by reducing the amount of acid produced in the stomach, while H2 blockers block histamine receptors, which stimulates acid production. Antibiotics may also be prescribed to treat bacterial infections like H. pylori that can cause gastritis. Maintaining a healthy lifestyle through diet and stress management helps prevent recurrence of gastritis.
The Gastritis Treatment Market is estimated to be valued at US$ 131.76 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growing geriatric population is a key driver for the gastritis treatment market. Older adults are more prone to develop gastric and duodenal ulcers that can lead to gastritis. According to the United Nations, by 2050, one in six people in the world will be over age 65, up from one in 11 in 2019. This growing susceptible patient pool will drive greater demand for gastritis treatments. Furthermore, increasing pollution levels leading to poor air quality are also contributing to rising acid reflux conditions and gastritis prevalence. Exposure to vehicular emissions, dust and other allergens exacerbate gastric inflammation. This environmental factor thus drives the need for anti-gastritis medications and supplements.
Segment Analysis
The global Gastritis Treatment market is dominated by the proton pump inhibitors (PPI) sub-segment. PPIs work by reducing the amount of acid produced in the stomach. Popular PPI drugs that are widely used for gastritis treatment include Nexium, Prilosec and Prevacid. Long-term use of PPIs is safe for most people with gastritis, however, they are associated with few side effects like increased risk of bacterial infections.
PEST Analysis
Political: Changes in regulatory policies related to drug approval can impact the development of new treatment options for gastritis.
Economic: Rise in per capita healthcare expenditure in developing countries is fueling market growth. However, high cost of PPI drugs remains a challenge.
Social: Growing awareness about lifestyle changes required for gastritis management is driving preventive healthcare. Widespread adoption of junk food consumption can increase gastritis cases.
Technological: Advancements in pharmaceutical drug delivery systems are helping improve medication effectiveness and compliance for long-term gastritis treatment.
Key Takeaways
The global Gastritis Treatment market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing prevalence of H. pylori infection and growing geriatric population who are more prone to gastric disorders.
Regionally, North America commands the largest share in the gastritis treatment market due to strong regional healthcare infrastructure and high adoption of advanced drugs. The Asia Pacific market is expected to grow at the fastest pace during the forecast period.
Key players operating in the Gastritis Treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, and Takeda Pharmaceutical Company Limited. Pfizer holds the leading market position with its popular PPI drugs like Nexium and Prilosec.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
